Crispr Therapeutics price target lowered to $123 from $153 at Chardan

Chardan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $123 from $153 and keeps a Buy rating on the shares after the company reported FY22 results, stating that exa-cel launch prep "appears to be progressing well." The firm, which updated its model for 2022 financials, a more conservative valuation of the I/O cell therapy platform, and a slower ramp for exa-cel, said it continues to believe Vertex’s (VRTX) global network and commercial expertise should help position exa-cel for a successful launch.